Evidence map›Paper›PMID 29479834›Full record

ArticleCancer medicine2018

Validating the pivotal role of the immune system in low-dose radiation-induced tumor inhibition in Lewis lung cancer-bearing mice.

Lei Zhou, Xiaoying Zhang, Hui Li, Chao Niu, Dehai Yu, Guozi Yang, Xinyue Liang, Xue Wen, Min Li, Jiuwei Cui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Low-Dose Non-Targeted Effects and Mitochondrial Control.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Review
  13. Review
  14. Use of Multi-Site Radiation Therapy for Systemic Disease Control.International journal of radiation oncology, biology, physics · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lei ZhouCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Xiaoying ZhangCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Hui LiCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Chao NiuCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Dehai YuCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Guozi YangDepartment of Radiation-Oncology, The First Hospital of Jilin University, Changchun, 130021, China.
Xinyue LiangCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Xue WenCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Min LiCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Jiuwei CuiCancer Center, The First Hospital of Jilin University, Changchun, 130021, China.ORCID 0000-0001-6496-7550
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although low-dose radiation (LDR) possesses the two distinct functions of inducing hormesis and adaptive responses, which result in immune enhancement and tumor inhibition, its clinical applications have not yet been elucidated. The major obstacle that hinders the application of LDR in the clinical setting is that the mechanisms underlying induction of tumor inhibition are unclear, and the risks associated with LDR are still unknown. Thus, to overcome this obstacle and elucidate the mechanisms mediating the antitumor effects of LDR, in this study, we established an in vivo lung cancer model to investigate the participation of the immune system in LDR-induced tumor inhibition and validated the pivotal role of the immune system by impairing immunity with high-dose radiation (HDR) of 1 Gy. Additionally, the LDR-induced adaptive response of the immune system was also observed by sequential HDR treatment in this mouse model. We found that LDR-activated T cells and natural killer cells and increased the cytotoxicity of splenocytes and the infiltration of T cells in the tumor tissues. In contrast, when immune function was impaired by HDR pretreatment, LDR could not induce tumor inhibition. However, when LDR was administered before HDR, the immunity could be protected from impairment, and tumor growth could be inhibited to some extent, indicating the induction of the immune adaptive response by LDR. Therefore, we demonstrated that immune enhancement played a key role in LDR-induced tumor inhibition. These findings emphasized the importance of the immune response in tumor radiotherapy and may help promote the application of LDR as a novel approach in clinical practice.

Indexed as

Radiation, IonizingAnimalsBiomarkersCarcinoma, Lewis LungCytokinesDisease Models, AnimalFemaleImmune SystemImmunohistochemistryImmunomodulationKiller Cells, NaturalLymphocyte ActivationLymphocytes, Tumor-InfiltratingMiceRadiation DosageSpleenBiomarkersCytokinesHigh-dose radiationimmune enhancementlow-dose radiationlung cancermouse model

Identifiers

PMID29479834
PMCPMC5911597
OpenAlexW2790605702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.